Biologics
A guide to manufacturing biologics
July 07 by Leila HawkinsPharma IQ explores the complexities of manufacturing biologics
How Sanofi is using AI to accelerate time to market for new drugs
June 06 by Leila HawkinsLearn more about how AI can accelerate the drug discovery process
What are the Real Drivers in the Disposables Market?
February 05 by Tony HitchcockIn my last blog ahead of the Disposables Solutions meeting in Munich next month, I said that I would be looking a two key areas, which would feature in the discussion sessions during the meeting, th...
Reducing Late-Stage Biologic Failure with Immune Assays- An Interview with Harald Kropshofer
November 27 by Gerald ClarkeThere have been some high profile cases of antibodies causing severe reactions, as well as posing a high risk to patients, these late stage failures are hugely costly. Is there a way to prevent or pre...
Pharmaceutical Manufacturing Facilities Rapidly Becoming Obsolete
October 21 by Pharma IQ NewsJones Lang LaSalle reports the key considerations for transforming existing facilities to meet the rising demand for biologic medicines Traditional pharmaceutical manufacturing facilities are being d...
Pathogen Safety Today
October 09 by Pharmaceuticals & Biotechnology EditorAs pathogens continue to adapt and develop so must your strategy to prevent contamination. With both the financial cost and the damage to reputation so high is it critical to keep at the cutting edg...
Regulatory Guidelines for Viral Safety
August 22 by Pharma IQS. Steve Zhou, Ph.D. Microbac Laboratories, Inc., said in Biopharmaceutical Process Evaluated for Viral Clearance: “Regulatory expectations on viral safety for biopharmaceutical products have evolved...
Improving the Security, Quality & Compliance of your Biologic Operation
February 21 by Pharma IQIn the coming years, biologics are expected to make up a greater proportion of revenue growth for pharmaceutical companies, with some figures placing it as high as 60 per cent. The US Food...
Biosimilar Capabilities and Market Potential in Asia
June 29 by Pharma IQEpogen, Neupogen and Enbrel are three biologics which have already seen their patents expire, and Herceptin and Avastin are to be added to this list in the not too distant future. By 2015 the global...
3 Top Security-Enhancing Tips for Reducing Cargo Thefts
March 15 by Andrea CharlesBarry Tarnef, Assistant Vice President, Senior Loss Control Specialist, Chubb & Son, speaks to Andrea Charles from Pharma IQ, about current risk management trends in the supply chain f...
Has Your Supply Chain Had a Health Check Recently?
March 10 by Amber ScorahReliable, on-time delivery and distribution are vital components of a healthy supply chain. Streamlining distribution processes while improving quality and lowering costs are all key. Evaluati...
Key Facility Considerations for Meeting Biologics Demand
April 24 by Roger HumphreyBuilding a new or outfitting an existing facility to support biologic systems is a mammoth undertaking by any measure. The following questions are key issues facing life sciences companies as they upd...